The University of Kansas Cancer Center (KUCC) is a matrix cancer center that includes: the University of Kansas Medical Center campuses in Kansas City, Wichita and Salina, the University of Kansas in Lawrence and via consortium agreement, the Stowers Institute for Medical Research and Children's Mercy Kansas City. In 2015, 187 members of KUCC accounted for $13.4M of NCI funding and a total of $61.2M in overall cancer- related funding, an increase of $10M during the previous funding period. Roy A. Jensen, MD, who is supported by a strong, nationally recognized leadership team, leads KUCC. Over the last four years substantial progress has been made broadening partnerships with communities throughout the KUCC catchment area, boosting recruitment of physician-scientists, augmenting clinical research and early-phase clinical trials, advancing education for the next generation of scientists and health care providers and heightening influence for KUCC researchers in the national scientific community. KUCC has established four specific aims to ensure KUCC leads in the fight against cancer: 1. Leverage unique institutional and regional assets to become a leading academic institution for transforming discoveries from the laboratory into new anticancer drug therapies; 2. Provide the optimal environment to focus the power of precision medicine, basic science inquiry, drug discovery and development, and behavioral interventions to decrease cancer incidence, morbidity and mortality; 3. Be a nationally recognized leader in partnering with key stakeholders, community advocates and regional leaders to develop, promote, and foster the adoption and implementation of research-based cancer prevention, diagnosis, treatment, control, and survivorship practices throughout the KUCC catchment area to mitigate the impact of cancer; and 4. Provide leadership in envisioning, developing and implementing a thoughtful, comprehensive strategy to educate the next generation of physician-scientists and allied investigators in cancer research, treatment, prevention and control. To accomplish these goals KUCC has four research programs: Cancer Biology, Cancer Control and Population Health, Cancer Prevention and Survivorship, and Drug Discovery, Delivery and Experimental Therapeutics. In addition, KUCC supports the Clinical Trials Office, five established shared resources - Biospecimen, Biostatistics and Informatics, Clinical Pharmacology, Lead Development and Optimization and Transgenic and Gene-Targeting ? along with three developing shared resources ? Cell Authentication and Pathogen Screening, Health Communications Research and Nutrition.

Public Health Relevance

KUCC aims to leverage unique regional scientific assets to build a nationally significant cancer research center that will become a leading institution for transforming discoveries in the laboratory into new therapeutic approaches. KUCC will expand its depth, breadth and impact and strive to become an NCI-designated comprehensive cancer center that meets the needs of the more than 4.4M Americans who live within the 92,000 square miles of the KUCC catchment area.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA168524-09S2
Application #
10203348
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Shafik, Hasnaa
Project Start
2012-07-11
Project End
2022-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
9
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Kansas
Department
Pathology
Type
Schools of Medicine
DUNS #
016060860
City
Kansas City
State
KS
Country
United States
Zip Code
66160
Kumar, Dhruv; New, Jacob; Vishwakarma, Vikalp et al. (2018) Cancer-Associated Fibroblasts Drive Glycolysis in a Targetable Signaling Loop Implicated in Head and Neck Squamous Cell Carcinoma Progression. Cancer Res 78:3769-3782
Vishwakarma, Vikalp; New, Jacob; Kumar, Dhruv et al. (2018) Potent Antitumor Effects of a Combination of Three Nutraceutical Compounds. Sci Rep 8:12163
Sharma, Priyanka; López-Tarruella, Sara; García-Saenz, José Angel et al. (2018) Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res 24:5820-5829
Snyder, Vusala; Reed-Newman, Tamika C; Arnold, Levi et al. (2018) Cancer Stem Cell Metabolism and Potential Therapeutic Targets. Front Oncol 8:203
Chen, Yvonnes; Fowler, Carina H; Papa, Vlad B et al. (2018) Adolescents' behavioral and neural responses to e-cigarette advertising. Addict Biol 23:761-771
Mudaranthakam, Dinesh Pal; Thompson, Jeffrey; Hu, Jinxiang et al. (2018) A Curated Cancer Clinical Outcomes Database (C3OD) for accelerating patient recruitment in cancer clinical trials. JAMIA Open 1:166-171
Ranjan, Atul; Iyer, Swathi V; Ward, Christopher et al. (2018) MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma. Oncotarget 9:21429-21443
Brody, Jonathan R; Dixon, Dan A (2018) Complex HuR function in pancreatic cancer cells. Wiley Interdiscip Rev RNA 9:e1469
Sharma, P; Barlow, W E; Godwin, A K et al. (2018) Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313). Ann Oncol 29:654-660
Campos, Camila D M; Gamage, Sachindra S T; Jackson, Joshua M et al. (2018) Microfluidic-based solid phase extraction of cell free DNA. Lab Chip 18:3459-3470

Showing the most recent 10 out of 177 publications